Lead potential Target large oncology and neurodegenerative research and clinical centers leveraging Telo Genomics' leading telomere analysis platform for prognostics and liquid biopsies. Highlight opportunities with Multiple Myeloma and Alzheimer’s disease cohorts, and offer integration with existing diagnostic workflows to improve patient stratification.

Strategic partnerships Pursue collaborations with academic institutions and pharma/drug developers for co-development and validation of telomere-based diagnostic and prognostic tests. Propose pilot studies or translational research programs that showcase real-world clinical utility and potential regulatory pathways.

Financial and leadership signals Leverage recent leadership appointments and CFO hire to discuss strategic financing rounds, grant opportunities, and budget planning for expanded clinical studies and commercialization activities. Position Telo Genomics as investing in scalable operations and robust evidence generation.

Industry exposure Capitalize on presence at hematology conferences and ASH interactions to schedule targeted meetings with leading hematologists and pathologists. Offer demonstrations of MRD profiling capabilities and how the platform can complement minimal residual disease assessments.

Technology and security Emphasize cloud-based scalability, data security, and AI-driven analytics as value-adds for large-scale biomarker studies. Propose end-to-end data solutions that integrate with cloud infrastructure and compliance frameworks to support multi-center trials and data sharing.